Cinclus Pharma (CINPHA) - Net Assets
Based on the latest financial reports, Cinclus Pharma (CINPHA) has net assets worth Skr202.70 Million SEK (≈ $21.81 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr424.54 Million ≈ $45.69 Million USD) and total liabilities (Skr221.84 Million ≈ $23.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CINPHA equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr202.70 Million |
| % of Total Assets | 47.74% |
| Annual Growth Rate | 42.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 63.52 |
Cinclus Pharma - Net Assets Trend (2022–2025)
This chart illustrates how Cinclus Pharma's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Cinclus Pharma market cap and net worth.
Annual Net Assets for Cinclus Pharma (2022–2025)
The table below shows the annual net assets of Cinclus Pharma from 2022 to 2025. Also explore CINPHA net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr369.39 Million ≈ $39.75 Million |
-33.48% |
| 2024-12-31 | Skr555.33 Million ≈ $59.76 Million |
+823.09% |
| 2023-12-31 | Skr-76.80 Million ≈ $-8.26 Million |
-160.53% |
| 2022-12-31 | Skr126.87 Million ≈ $13.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cinclus Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55863700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr1.32 Billion | 357.94% |
| Total Equity | Skr369.39 Million | 100.00% |
Cinclus Pharma Competitors by Market Cap
The table below lists competitors of Cinclus Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NTPM Holdings Bhd
KLSE:5066
|
$57.80 Million |
|
Univentures Public Company Limited
BK:UV
|
$57.81 Million |
|
T7 Global Bhd
KLSE:7228
|
$57.81 Million |
|
Chilwa Minerals Ltd
AU:CHW
|
$57.86 Million |
|
Land Securities Group PLC
LSE:LAND
|
$57.79 Million |
|
TETHYS PETROLEUM LTD
F:TP21
|
$57.74 Million |
|
Multifiling Mitra Indonesia
JK:MFMI
|
$57.71 Million |
|
Fiducial Office Solutions
PA:SACI
|
$57.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cinclus Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 555,330,000 to 369,391,000, a change of -185,939,000 (-33.5%).
- Net loss of 183,972,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-183.97 Million | -49.8% |
| Other Changes | Skr-1.97 Million | -0.53% |
| Total Change | Skr- | -33.48% |
Book Value vs Market Value Analysis
This analysis compares Cinclus Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.23x to 1.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Skr2.73 | Skr11.54 | x |
| 2023-12-31 | Skr-1.65 | Skr11.54 | x |
| 2024-12-31 | Skr11.93 | Skr11.54 | x |
| 2025-12-31 | Skr7.94 | Skr11.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cinclus Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -320.12%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.48x
- Recent ROE (-49.80%) is above the historical average (-69.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -196.32% | -2356.20% | 0.06x | 1.46x | Skr-261.76 Million |
| 2023 | 0.00% | -3609.97% | 0.06x | 0.00x | Skr-207.44 Million |
| 2024 | -30.26% | -3668.80% | 0.01x | 1.08x | Skr-223.56 Million |
| 2025 | -49.80% | -320.12% | 0.11x | 1.48x | Skr-220.91 Million |
Industry Comparison
This section compares Cinclus Pharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $173,655,734
- Average return on equity (ROE) among peers: -27.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cinclus Pharma (CINPHA) | Skr202.70 Million | -196.32% | 1.09x | $57.79 Million |
| BioGaia AB (publ) (BIOG-B) | $456.79 Million | 71.58% | 0.13x | $1.15 Billion |
| Enzymatica publ AB (ENZY) | $110.70 Million | -28.41% | 0.21x | $48.59 Million |
| Enorama Pharma AB (ERMA) | $19.54 Million | -228.34% | 0.76x | $5.68 Million |
| Gabather AB (publ) (GABA) | $33.19 Million | -23.79% | 0.05x | $1.76 Million |
| Klaria Pharma Holding AB (KLAR) | $174.59 Million | -3.20% | 0.01x | $15.72 Million |
| Moberg Pharma AB (publ) (MOB) | $303.75 Million | 4.04% | 0.18x | $53.61 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $111.36 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $38.47 Million | -14.45% | 0.11x | $7.36 Million |
| Orexo AB (ORX) | $324.35 Million | -10.16% | 0.17x | $48.54 Million |
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more